Overview

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

Status:
Unknown status

Trial end date:
2020-05-01

Target enrollment:

Participant gender:

Summary

The trial will evaluate the optimal treatment with nab-paclitaxel in combination with either carboplatin or gemcitabine for patients with triple negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

West German Study Group

Collaborators:

Celgene
Celgene Corporation

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Gemcitabine
Paclitaxel